<p>Prime Medicine（納斯達克股票代碼：PRME - 獲取免費報告）在週二的一份研究報告中被華爾街 Zen 的股票研究分析師從 “強烈賣出” 評級上調至 “賣出” 評級。</p>
<p>獲取 <strong>Prime Medicine</strong> 的提醒：</p>
<p>PRME 近期成為多份報告的主題。Lifesci Capital 在 3 月 2 日的研究報告中將 Prime Medicine 的股票評級上調至 “強烈買入”。Oppenheimer 在 3 月 12 日的報告中開始覆蓋 Prime Medicine 的股票。他們給予該股票 “跑贏大盤” 的評級，並設定了 11.00 美元的目標價。一位研究分析師給予該股票 “強烈買入” 評級，四位給予 “買入” 評級，三位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Prime Medicine 目前的共識評級為 “適度買入”，共識目標價為 7.38 美元。</p>
<p><strong>獲取我們關於 PRME 的最新報告</strong></p>
<h2>Prime Medicine 股票表現</h2>
<p>週二，PRME 的開盤價為 3.47 美元。Prime Medicine 的 52 周低點為 1.11 美元，52 周高點為 6.94 美元。該公司的 50 日移動平均線為 3.72 美元，200 日移動平均線為 3.90 美元。該公司的市值為 6.2675 億美元，市盈率為-2.57，貝塔值為 2.35。</p>
<h2>機構投資者對 Prime Medicine 的看法</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對該公司的持股。AQR Capital Management LLC 在第一季度將其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前擁有 243,795 股該公司的股票，價值 48.5 萬美元，此前在此期間購買了額外的 227,749 股。Jacobs Levy Equity Management Inc. 在第一季度購買了 Prime Medicine 的新頭寸，價值約為 101,000 美元。Rhumbline Advisers 在第一季度將其在 Prime Medicine 的持股比例提高了 13.8%。Rhumbline Advisers 目前擁有 81,900 股該公司的股票，價值 163,000 美元，此前在此期間購買了額外的 9,944 股。Creative Planning 在第二季度購買了 Prime Medicine 的新股份，價值約為 25,000 美元。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度將其在 Prime Medicine 的持股比例提高了 253.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 119,856 股該公司的股票，價值 29.6 萬美元，此前在上個季度購買了額外的 85,938 股。當前 70.37% 的股票由機構投資者持有。</p>
<h2>關於 Prime Medicine</h2>
<p>（獲取免費報告）</p>
<p>我們是一家生物技術公司，致力於提供一種新型的差異化一次性治癒性基因療法——Prime Editors，以通過部署我們的 Prime Editing 技術來解決最廣泛的疾病譜系。我們認為這是一種多功能、精確、高效且廣泛的基因編輯技術。與疾病相關的基因突變多種多樣，可能從單個鹼基的錯誤（稱為點突變）到超出單個鹼基的錯誤，例如插入、缺失、重複或其組合。</p>
<h2>另請參見</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Prime Medicine</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
<p>在你考慮 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中有 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PRME

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

<p>華爾街禪將 Prime Medicine（NASDAQ:PRME）的評級從 “強烈賣出” 上調至 “賣出”。該股票的共識評級為 “適度買入”，目標價格為 7.38 美元。PRME 的開盤價為 3.47 美元，52 周價格區間為 1.11 美元至 6.94 美元。機構投資者持有該股票的 70.37%，AQR Capital Management 等公司的持股比例顯著增加。Prime Medicine 專注於使用 Prime Editing 技術進行治癒性基因療法</p>

<p>Prime Medicine (NASDAQ:PRME - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a research note issued on Tuesday.</p>
<div class="lb-trans"><p>Prime Medicine（納斯達克股票代碼：PRME - 獲取免費報告）在週二的一份研究報告中被華爾街 Zen 的股票研究分析師從 “強烈賣出” 評級上調至 “賣出” 評級。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><p>PRME has been the topic of a number of other reports. Lifesci Capital upgraded shares of Prime Medicine to a &#34;strong-buy&#34; rating in a research note on Monday, March 2nd. Oppenheimer assumed coverage on shares of Prime Medicine in a report on Thursday, March 12th. They issued an &#34;outperform&#34; rating and a $11.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Prime Medicine currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.38.</p>
<div class="lb-trans"><p>PRME 近期成為多份報告的主題。Lifesci Capital 在 3 月 2 日的研究報告中將 Prime Medicine 的股票評級上調至 “強烈買入”。Oppenheimer 在 3 月 12 日的報告中開始覆蓋 Prime Medicine 的股票。他們給予該股票 “跑贏大盤” 的評級，並設定了 11.00 美元的目標價。一位研究分析師給予該股票 “強烈買入” 評級，四位給予 “買入” 評級，三位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Prime Medicine 目前的共識評級為 “適度買入”，共識目標價為 7.38 美元。</p>
</div><p><strong>Get Our Latest Report on PRME</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 PRME 的最新報告</strong></p>
</div><h2>Prime Medicine Stock Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 股票表現</h2>
</div><p>PRME opened at $3.47 on Tuesday. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.94. The firm has a 50-day moving average of $3.72 and a 200 day moving average of $3.90. The firm has a market cap of $626.75 million, a P/E ratio of -2.57 and a beta of 2.35.</p>
<div class="lb-trans"><p>週二，PRME 的開盤價為 3.47 美元。Prime Medicine 的 52 周低點為 1.11 美元，52 周高點為 6.94 美元。該公司的 50 日移動平均線為 3.72 美元，200 日移動平均線為 3.90 美元。該公司的市值為 6.2675 億美元，市盈率為-2.57，貝塔值為 2.35。</p>
</div><h2>Institutional Investors Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>機構投資者對 Prime Medicine 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Prime Medicine by 1,419.4% during the first quarter. AQR Capital Management LLC now owns 243,795 shares of the company's stock worth $485,000 after purchasing an additional 227,749 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Prime Medicine in the first quarter worth about $101,000. Rhumbline Advisers raised its position in shares of Prime Medicine by 13.8% in the first quarter. Rhumbline Advisers now owns 81,900 shares of the company's stock valued at $163,000 after purchasing an additional 9,944 shares during the period. Creative Planning bought a new stake in shares of Prime Medicine in the second quarter valued at approximately $25,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Prime Medicine by 253.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 119,856 shares of the company's stock valued at $296,000 after buying an additional 85,938 shares in the last quarter. 70.37% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對該公司的持股。AQR Capital Management LLC 在第一季度將其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前擁有 243,795 股該公司的股票，價值 48.5 萬美元，此前在此期間購買了額外的 227,749 股。Jacobs Levy Equity Management Inc. 在第一季度購買了 Prime Medicine 的新頭寸，價值約為 101,000 美元。Rhumbline Advisers 在第一季度將其在 Prime Medicine 的持股比例提高了 13.8%。Rhumbline Advisers 目前擁有 81,900 股該公司的股票，價值 163,000 美元，此前在此期間購買了額外的 9,944 股。Creative Planning 在第二季度購買了 Prime Medicine 的新股份，價值約為 25,000 美元。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度將其在 Prime Medicine 的持股比例提高了 253.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 119,856 股該公司的股票，價值 29.6 萬美元，此前在上個季度購買了額外的 85,938 股。當前 70.37% 的股票由機構投資者持有。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>關於 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.</p>
<div class="lb-trans"><p>我們是一家生物技術公司，致力於提供一種新型的差異化一次性治癒性基因療法——Prime Editors，以通過部署我們的 Prime Editing 技術來解決最廣泛的疾病譜系。我們認為這是一種多功能、精確、高效且廣泛的基因編輯技術。與疾病相關的基因突變多種多樣，可能從單個鹼基的錯誤（稱為點突變）到超出單個鹼基的錯誤，例如插入、缺失、重複或其組合。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參見</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Prime Medicine</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PRME"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中有 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen

Market Beat

Prime Medicine

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

標普生物技術 3 倍做多 - Direxion

奧本海默控股

Prime Medicine（納斯達克代碼：PRME）在 Wall Street Zen 被調升至賣出評級